4.5 Article

PharmGKB and the international warfarin pharmacogenetlics consortium: The changing role for pharmacogenomic databases and single-drug pharmacogenetics

Journal

HUMAN MUTATION
Volume 29, Issue 4, Pages 456-460

Publisher

WILEY-LISS
DOI: 10.1002/humu.20731

Keywords

warfarin; CYP2C9; VKORC1; pharmacogenetics; pharmacogenomics; PharmGKB; SNPs; IWPC

Funding

  1. NIGMS NIH HHS [UO1GM61374] Funding Source: Medline

Ask authors/readers for more resources

PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base (www.pharmgkb.org) is a publicly available online resource dedicated to the dissemination of how genetic variation leads to variation in drug responses. The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research. PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries. Recently, PharmGKB has embraced a new role-broker of pharmacogenomic data for data sharing consortia. In particular, we have helped create the International Warfarin Pharmacogenetics Consortium (IWPC), which is devoted to pooling genotype and phenotype data relevant to the anticoagulant warfarin. PharmGKI3 has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available